The ILCN is aware that the situation with telehealth differs across regions and that lack of access to technology is a huge obstacle. We would love to hear from IASLC members around the globe about your experiences. Please email us at [email protected]. Read more
Most cancer immunotherapies currently in development aim to stimulate antitumor T-cell responses either by adoptive transfer of in vitro expanded native or genetically modified T lymphocytes targeting malignant cells,1 ,2 […] Read more
A leading cause of mortality worldwide, cancer was tied to nearly 10 million deaths in 2020.1 Lung cancer has remained unchallenged for more than 30 years as the most commonly […] Read more
Since December 2019, the world has been mired in a pandemic that has displaced other 21st-century health priorities for many populations. The social significance and speed of contagion from COVID-19 […] Read more
It has been just over a year since we reported how oncogene-driven patient advocacy groups are disrupting the research paradigm in lung cancer.1 We have indeed come a long way […] Read more
Transbronchial Microwave Ablation of Malignant Lung Nodules: Outcomes, Challenges, and Perspective
+more
With increasing availability of CT scans and strong evidence for the utility of low-dose CT screening in high-risk populations,1 an increasing number of small lung nodules are being incidentally discovered. […] Read more
Surgical resection is the most effective treatment for patients with early-stage NSCLC.1 However, approximately 25% of these patients do not undergo resection, usually because of underlying comorbidities precluding surgery or […] Read more
June 23, 2021—Savolitinib was approved in China for treatment of patients with NSCLC with MET exon 14 skipping alterations whose disease has progressed following systemic treatment or who are […] Read more
July 19—The National Medical Products Administration in China approved durvalumab in combination with standard-of-care platinum chemotherapy (as defined as etoposide plus carboplatin or cisplatin) for the first-line management of extensive-stage […] Read more
CheckMate-816 made quite a splash at both the AACR Annual Meeting 2021 and the 2021 ASCO Annual Meeting’s virtual podium, and the accompanying article by Patrick Forde, MD, explains why. Dr. Forde, who is director of the Thoracic Oncology Clinical Research Program and associate professor of Oncology at Johns Hopkins... Read more